Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Valneva SENASDAQ: VALN

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of €32.07M (cash outflow) rose 247.4% year over year, ahead of the +81.9% change in trailing-twelve-month net income. Sequentially, it fell 44.9% from the prior quarter. Over 3 fiscal years it compounded at -7.0% a year.

Context

  • Net income amounted to 66.0% of revenue in FY2025, up 58.7 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -€77.65M (-32.6%) for the fiscal year ending Dec 2026, a slowdown from the +840.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€32.07M-44.9% QoQ
Last fiscal yearDec 2025
-€115.19M+840.6% YoY
LTMMar 2026
-€146.23M+81.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+247.4%+47.7%-199.7 pp
1 year+840.6%-32.6%-873.2 pp
3-year CAGR-7.0%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the cash flow

Latest · FY2025
(115.19M) EUR
Year-over-year change
-840.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +81.9% is the 3rd highest of 8, against a peer median of -10.5%.
  • Net income amounts to 93.5% of revenue for VALN, versus a peer median of 173.5%.
VALN Competitors
Net Income for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$2.79B USD-10.5%—110.5%
PCVXVaxcyte, Inc.LTM Jun 2026$1.38B USD+152.9%+50.8%—
IBRXImmunityBio, Inc.LTM Sep 2026$1.11B USD+218.3%-5.5%607.8%
VIRVir Biotechnology, Inc.LTM Mar 2026$442.72M USD-23.4%—676.0%
VALNValneva SELTM Mar 2026€146.23M EUR+81.9%-7.0%93.5%
NVAXNovavax, Inc.LTM Mar 2026$87.84M USD-118.3%—14.7%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$84.93M USD-12.0%-32.8%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M USD+15.4%—173.5%
Peer median (excluding VALN) —-10.5%-5.5%173.5%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
Deferred Income Tax3.45M(1.54M)2.8M761K1.07M
Stock-Based Compensation14.51M(8.66M)5.11M7.98M9.53M
Change in Working Capital36.13M(145.98M)(145.06M)(11.57M)(148K)
Accounts Receivables(21.35M)12.4M(2.86M)15.71M13.33M
Inventory(92.37M)84.22M(9.17M)(6.8M)1.03M
Accounts Payables35.24M(14.05M)(17.4M)00
Other Working Capital114.61M(228.55M)(115.65M)(20.48M)(14.51M)
Other Non-Cash Items81.96M33.07M18.25M(71.72M)30.09M
Operating Cash Flow76.9M(245.34M)(202.74M)(67.22M)(52.89M)
Capital Expenditures(93.17M)(29.32M)(14.31M)(16.44M)(4.48M)
Acquisitions (Net)08K(10.95M)00
Purchases of Investments00000
Sales of Investments0000841K
Other Investing Activities55K260K4.6M90.78M1.87M
Investing Cash Flow(93.12M)(29.05M)(20.59M)76.92M(1.71M)
Debt Repayment(3.9M)34.49M75.89M(6.49M)61K
Common Stock Issued166.82M189.84M0030M
Common Stock Repurchased00(240K)00
Dividends Paid00000
Other Financing Activities(8.42M)(9.21M)(12.57M)(19.97M)(30.69M)
Financing Cash Flow154.5M215.12M63.08M30.68M(621K)
Effect of Forex Changes3.96M(828K)(204K)1.81M(3.4M)
Net Change in Cash142.29M(57.21M)(160.45M)42.19M(58.62M)
Free Cash Flow(16.27M)(274.67M)(217.06M)(83.66M)(57.38M)

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.